Induction of remission in rheumatoid arthritis: Criteria and opportunities

Rheumatology International

Volumn 29, Issue 2, 2008, Pages 131-139

  Valesini, Guido ^a   Di Franco, Manuela ^a   Spinelli, Francesca Romana ^a   Scrivo, Rossana ^a  

^a POLICLINICO UMBERTO I   (Italy)

Author keywords

DMARD; Prognostic factors; Remission criteria; Rheumatoid arthritis

Indexed keywords

ABATACEPT; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE;

CLINICAL PRACTICE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DISABILITY; DISEASE CLASSIFICATION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DRUG THERAPY, COMBINATION; HUMANS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 55949103449     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-008-0699-0     Document Type: Review

References (46)

1. T Pincus A Kavanaugh D Aletaha J Smolen 2006 Complexities in defining remission in rheumatic diseases Clin Exp Rheumatol 24 Suppl 43 S1 S6
2. JS Smolen D Aletaha 2006 What should be our treatment goal in rheumatoid arthritis today? Clin Exp Rheumatol 24 Suppl 43 S7 S13
3. H Maekinen P Hannonen T Sokka 2006 Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomized clinical trials for the rate of remission Clin Exp Rheumatol 24 Suppl 43 S22 S28
4. R Landewé D van der Heijde S van der Linden M Boers 2006 Twenty-eight joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission Ann Rheum Dis 65 637 641 10.1136/ard.2005.039859
5. L Gossec M Dougados P Goupille A Cantagrel J Sibilia O Meyer 2004 Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study Ann Rheum Dis 63 675 680 10.1136/ard.2003.010611
6. ETH Molenaar AE Voskuyl IE van der Horst-Bruinsma GMT Schreuder E Zanelli BAC Dijkmans 2002 Influence of HLA polymorphism on persistent remission in rheumatoid arthritis Ann Rheum Dis 61 351 353 10.1136/ard.61.4.351
7. M Drozdzik T Rudas A Pawlik M Kurzawski B Czerny W Gornik 2006 The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs Eur J Clin Pharmacol 62 933 937 10.1007/s00228-006-0192-1
8. SMM Verstappen GA van Albada-Kuipers JWJ Bijlsma AAM Blaauw Y Schenk HCM Haanen JWG Jacobs On behalf of the Utrecht Rheumatoid Arthritis Cohort Study Group 2005 A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow-up Ann Rheum Dis 64 38 43 10.1136/ard.2003.014928
9. K Forslind I Hafstroem M Ahlmen B Svensson for the BARFOT study group 2007 Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis 66 46 52 10.1136/ard.2006.056937
10. FC Breedveld JR Kalden 2004 Appropriate and effective management of rheumatoid arthritis Ann Rheum Dis 63 627 633 10.1136/ard.2003.011395
11. CA Sesin CO Bingham 2005 Remission in rheumatoid arthritis: wishful thinking or clinical reality? Semin Arthritis Rheum 35 185 196 10.1016/j.semarthrit.2005.06.003
12. C Grigor H Capell A Stirling AD McMahon P Lock R Vallance 2004 Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomized controlled trial Lancet 364 263 269 10.1016/S0140-6736(04)16676-2
13. H Maekinen H Kautiainen P Hannonen T Sokka 2005 Frequency of remissions in early rheumatoid arthritis defined by 3 sets of criteria. A 5-year follow-up study J Rheumatol 32 796 800
14. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793-2806
15. Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS (2007) Assessing remission in clinical practice. Rheumatology 1-5
16. Van der Helm-van Mil AHM, Breedveld FC, Huizinga TWJ (2006) Definition of disease states in early arthritis: remission versus minimal disease activity. Arthritis Res Ther 8:216. doi: 10.1186/ar1983
17. AK Brown MA Quinn Z Karim PG Conaghan CG Peterfy E Hensor 2006 Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission. Evidence from an imaging study may explain structural progression Arthritis Rheum 54 3761 3773 10.1002/art.22190
18. AE Voskuyl BAC Dijkmans 2006 Remission and radiographic progression in rheumatoid arthritis Clin Exp Rheumatol 24 Suppl 43 S37 S40
19. YPM Goekoop-Ruiterman JK de Vries-Bouwstra CF Allart D van Zeben PJSM Kerstens MW Hazes 2007 Comparison of treatment strategies in early rheumatoid arthritis. A randomized trial Ann Intern Med 146 406 415
20. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines 2002 Guidelines for the management of rheumatoid arthritis 2002 update Arthritis Rheum 46 328 346 10.1002/art.10148
21. MC Hochberg MG Lebwohl SE Plevy KF Hobbs DE Yocum 2005 The benefit/risk profile of TNF-blocking agents: findings of a consensus panel Semin Arthritis Rheum 34 819 836 10.1016/j.semarthrit.2004.11.006
22. G Valesini C Montecucco M Cutolo 2006 Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy Clin Exp Rheumatol 24 4 413 423
23. B Fautrel A Constantin J Morel O Vittecoq A Cantagrel B Combe 2006 Recommendations of the French Society for Rheumatology. TNFα antagonist therapy in rheumatoid arthritis Joint Bone Spine 73 433 441 10.1016/j.jbspin. 2006.04.001
24. AC Cannella JR O'Dell 2003 Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis? Curr Opin Rheumatol 15 185 192 10.1097/00002281-200305000-00003
25. T Sokka P Hannonen T Moettoenen 2005 Conventional disease-modifying antirheumatic drugs in early arthritis Rheum Dis Clin North Am 31 729 744 10.1016/j.rdc.2005.07.007
26. M Boers AC Verhoeven HM Markusse 1997 Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis Lancet 350 309 318 10.1016/S0140-6736(97) 01300-7
27. Möttönen T, Hannonen P, Leirisalo-Repo M et al, for the FIN_RACo trial group (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomized trial. Lancet 353:1568-1573
28. M Dougados P Emery EM Lemmel R de la Serna CA Zerbini S Brin 2003 Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data J Rheumatol 30 2572 2579
29. Van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, for the TEMPO study investigators (2006) Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis. Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54:1063-1074. doi: 10.1002/art.21655
30. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, von Vollehoven R et al. for the PREMIER investigators. The PREMIER study (2006) A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26-37. doi: 10.1002/art.21519
31. KL Hyrich DP Symmons KD Watson AJ Silman On behalf of the British Society for Rheumatology Biologics Register 2006 Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register Arthritis Rheum 54 1786 1794 10.1002/art.21830
32. St Clair EW, van der Heijde DMFM, Smolen JS et al. for the active controlled study of patients receiving infiliximab for the treatment of rheumatoid arthritis of early onset study group (2004). Arthritis Rheum 50:3432-3443. doi: 10.1002/art.20568
33. Hyrich KL, Watson KD, Silman AJ, Symmons DPM and the BSR Biologics Register (2006b) Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 45:1558-1565. doi: 10.1093/rheumatology/kel149
34. JM Kremer HK Genant LW Moreland AS Russell P Emery C Abud-Mendoza 2006 Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial Ann Intern Med 144 865 876
35. MC Genovese JC Becker M Schiff M Luggen Y Sherrer J Kremer 2005 Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition N Engl J Med 353 1114 1123 10.1056/NEJMoa050524
36. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S et al (2007) Efficacy and safety of abatacept or infliximab versus placebo in ATTEST: a phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis published online 29 Nov 2007
37. SB Coehn P Emery MW Greenwald M Dougados RA Furie MC Genovese 2006 Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks Arthritis Rheum 54 2793 2806 10.1002/art.22025
38. B Combe R Landewe C Lukas HD Bolosiu F Breedveld M Dougados 2007 EULAR recommendations for the management of early arthritis: report of a task force of the European standing committee for international clinical studies including therapeutics (ESCISIT) Ann Rheum Dis 66 34 45 10.1136/ard.2005.044354
39. T Möttönen P Hannonen M Korpela for the FIN_RACo trial group 2002 Delay to institution of therapy and induction of remission using single-drug or combination disease modifying antirheumatic drug therapy in early rheumatoid arthritis Arthritis Rheum 46 894 898 10.1002/art.10135
40. JJ Anderson G Wells AC Verhoeven DT Felson 2000 Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration Arthritis Rheum 43 22 29 10.1002/1529-0131(200001)43:1<22::AID- ANR4>3.0.CO;2-9
41. DE Furst FC Breedveld JR Kalden JS Smolen GR Burmester J Sieper 2007 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Ann Rheum Dis 66 2 22
42. D Aletaha JS Smolen 2006 Remission of rheumatoid arthritis: should we care about definitions? Clin Exp Rheumatol 24 Suppl 43 S45 S51
43. I Rupp HC Boshuizen HJ Dinant CE Jacobi GAM van der Bos 2006 Disability and health-related quality of life among patients with rheumatoid arthritis: association with radiographic joint damage, disease activity, pain, and depressive symptoms Scand J Rheumatol 35 175 181 10.1080/03009740500343260
44. TK Kvien T Uhlig 2005 Quality of life in rheumatoid arthritis Scand J Rheumatol 34 333 341 10.1080/03009740500327727
45. E Krishnan A Haekkinen T Sokka P Hannonen 2005 Impact of age and comorbidities on the criteria for remission and response in rheumatoid arthritis Ann Rheum Dis 64 1350 1352 10.1136/ard.2005.037903
46. I Rupp H Boshuizen CE Jacobi HJ Dinant GAM van den Bos 2004 Comorbidity in patients with rheumatoid arthritis: effect on health-related quality of life J Rheumatol 31 58 65